Navigation Links
QLT reports initial proof of concept data for punctal plug delivery technology
Date:5/12/2008

oday are an early indication that QLT's drug elution technology has the potential to provide a meaningful therapeutic benefit. To generate proof of concept data for the Company's proprietary punctal plug drug delivery system, QLT is currently enrolling patients in the CORE study, a Phase 2, randomized, double blind trial to assess the safety and efficacy of its latanoprost punctal plug delivery system for the treatment of glaucoma and ocular hypertension at three different doses (low, medium, high). The medium dose of latanoprost in the CORE Study was used in the trial that is being reported today.

About QLT

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. For more information, visit our web site at http://www.qltinc.com.

QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.

Atrigel is a registered trademark of QLT USA, Inc.

Visudyne is a registered trademark of Novartis AG.

Eligard is a registered trademark of Sanofi-aventis.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

Certain statements contained in this press release, which are not historical facts, are "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to: our beliefs re
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies Reports Third Quarter Financial Results
2. Bionovo Reports First Quarter 2008 Financial Results
3. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
4. Cardium Reports on First Quarter 2008 Highlights and Financial Results
5. Novavax Reports First Quarter 2008 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
7. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
8. Pharmos Corporation Reports 2008 First Quarter Results
9. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
10. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
11. Favrille Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... ... R-Biopharm is proud to announce the RIDASCREEN® Gliadin Competitive ... been accepted by AOAC International as Official First Action method. The AOAC Official ... R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially celiac toxic ...
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... USA (PRWEB) , ... July 30, 2015 , ... ... microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , With ... Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4
... N.Y., March 20 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... pre-clinical program in Hepatitis C focused on the ... Inc. Presidio,is a private biotechnology company focused on ... backed by some of the,most prominent investors in ...
... Corporation, a leading,provider of fully integrated imaging ... of its real-time patient and resource,scheduler software, ... staff, rooms with drag and drop ease,delivering ... ROI., A free CardioSchedule Information Kit ...
... March 20 Amsterdam Molecular,Therapeutics (Euronext: AMT), a ... announced that AMT,s Supervisory Board has decided to ... Board at its Annual,General Meeting of shareholders on ... of TomTom (Euronext Amsterdam: TOM2), and has been,instrumental ...
Cached Biology Technology:XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals 2XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals 3XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals 4LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems 2Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board 2Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board 3
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... A major initiative to create alternative nesting sites for the ... help protect juvenile salmon and steelhead in the Columbia River ... nesting site at Crump Lake in southern Oregon, which was just ... more than 135 nesting pairs of Caspian terns, as well as ...
... called for Europe to invest more funds into the study ... role in the function of human cells and which are ... to Alzheimer,s. Common lipids such as cholesterol are known ... cells and tissues, but human cells contain thousands of different ...
... Belfast is appealing for help from the public in looking ... Activities such as aquaculture, shipping and recreational boating have led ... Now Queen,s is attempting to find out exactly where and how ... this it is asking for help from the public to record ...
Cached Biology News:Project succeeding to relocate Caspian terns 2Project succeeding to relocate Caspian terns 3Project succeeding to relocate Caspian terns 4Project succeeding to relocate Caspian terns 5Project succeeding to relocate Caspian terns 6Europe-wide investment in lipid research will help tackle disease, says new report 2Queen's marine biologist investigates aliens beneath the waves 2
...
... antibody-based immunoaffinity matrices, such as Sepharose ... without compromising antigen-antibody reactivity, the need ... has precluded the application of these ... CHEMICON Re-Blot Plus Western Blot Mild ...
Applications: Western blotting ...
Applications: Western blotting ...
Biology Products: